Track Moderna logo
Studies
144
Enrolment
67.2M
Countries
53
MRNA
$218.01 +738.2%
FAERS
796
TBA

Trial site register

Every geocoded trial-site cluster from ClinicalTrials.gov - click a row for the full registry detail.

Trial site register (live)

SiteCountryStudiesEnrolmentRecruitingCompletedPhasesLead conditionUpdatedStatus
Houston29.76, -95.36United States45286.14K527N/A, Phase 1, Phase 2, Phase 3, Phase 4SARS-CoV-22026-10-16recruiting
Austin30.27, -97.74United States36282.92K227N/A, Phase 1, Phase 2, Phase 3, Phase 4SARS-CoV-22026-10-01recruiting
Philadelphia39.95, -75.16United States32241.49K516N/A, Phase 1, Phase 2, Phase 3, Phase 4SARS-CoV-22026-10-09recruiting
London51.51, -0.13United Kingdom26139.12K811Phase 1, Phase 2, Phase 3Influenza2026-10-16recruiting
Toronto43.71, -79.40Canada20175.4K46Phase 1, Phase 2, Phase 3Seasonal Influenza2026-10-16recruiting
Manchester53.48, -2.24United Kingdom17132.75K75N/A, Phase 1, Phase 2, Phase 3Propionic Acidemia2026-10-16recruiting
Madrid40.42, -3.70Spain1748.59K91N/A, Phase 1, Phase 2, Phase 3Propionic Acidemia2026-10-16recruiting
Québec46.81, -71.22Canada15164.45K27Phase 1, Phase 2, Phase 3Respiratory Syncytial Virus2026-10-16recruiting
Birmingham52.48, -1.90United Kingdom14126.53K66N/A, Phase 1, Phase 2, Phase 3Propionic Acidemia2026-09-29recruiting
Paris48.85, 2.35France1411.31K61N/A, Phase 1, Phase 2, Phase 3Propionic Acidemia2026-10-16recruiting
Seoul37.57, 126.98South Korea1288.55K33N/A, Phase 1, Phase 2, Phase 3Carcinoma, Non-Small-Cell Lung2026-10-16recruiting
Warsaw52.23, 21.01Poland1263.93K42Phase 1, Phase 2, Phase 3Non-small Cell Lung Cancer2026-10-16recruiting
Santiago-33.46, -70.65Chile1243.53K43Phase 1, Phase 2, Phase 3Respiratory Syncytial Virus2026-10-16recruiting
Barcelona41.39, 2.16Spain1235.73K42N/A, Phase 1, Phase 2, Phase 3Non-small Cell Lung Cancer2026-10-16recruiting
Taipei25.05, 121.53Taiwan11106.61K34Phase 1, Phase 2, Phase 3Carcinoma, Non-Small-Cell Lung2026-10-16recruiting
Nedlands-31.98, 115.81Australia1112.08K41Phase 1, Phase 2, Phase 3Non-small Cell Lung Cancer2026-10-16recruiting
Melbourne-37.81, 144.96Australia1111.75K34Phase 1, Phase 2, Phase 3Healthy Participants2026-09-18recruiting
Sherbrooke45.40, -71.90Canada1098.72K14Phase 1, Phase 2, Phase 3Respiratory Syncytial Virus2026-10-08recruiting
Poznan52.41, 16.93Poland1041.14K42Phase 1, Phase 2, Phase 3Non-small Cell Lung Cancer2026-10-16recruiting
Berlin52.52, 13.41Germany9110.24K04Phase 1, Phase 2, Phase 3Seasonal Influenza2026-09-29active
Taichung24.15, 120.68Taiwan9105.45K34Phase 2, Phase 3Non-small Cell Lung Cancer2026-10-16recruiting
Seville37.38, -5.97Spain910.33K50N/A, Phase 1, Phase 2, Phase 3Non-small Cell Lung Cancer2026-10-09recruiting
Panama City8.99, -79.52Panama883.78K05Phase 1, Phase 2, Phase 3Respiratory Syncytial Virus2026-09-29active
Buenos Aires-34.61, -58.38Argentina847.12K23Phase 2, Phase 3Respiratory Syncytial Virus2026-10-16recruiting
Tainan22.99, 120.21Taiwan828.72K32Phase 1, Phase 2, Phase 3Carcinoma, Non-Small-Cell Lung2026-10-16recruiting
Milan45.46, 9.19Italy84.5K40Phase 1, Phase 2, Phase 3Non-small Cell Lung Cancer2026-10-16recruiting
Camberwell-37.84, 145.07Australia790.25K04Phase 1, Phase 2, Phase 3Norovirus Acute Gastroenteritis2026-09-29active
San Juan18.47, -66.11Puerto Rico779.41K04Phase 1, Phase 2, Phase 3Respiratory Syncytial Virus2026-09-29active
Tokyo35.69, 139.69Japan758.16K15N/A, Phase 1, Phase 2, Phase 3SARS-CoV-22026-09-03recruiting
Bogotá4.61, -74.08Colombia711.09K32Phase 1, Phase 2, Phase 3Bladder Cancer2026-10-16recruiting
Rosario-32.95, -60.64Argentina78.46K31Phase 2, Phase 3Carcinoma, Non-Small-Cell Lung2026-10-16recruiting
Ankara39.92, 32.85Turkey (Türkiye)74.2K30Phase 1, Phase 2, Phase 3Non-small Cell Lung Cancer2026-10-16recruiting
Marseille43.30, 5.38France72.29K31N/A, Phase 1, Phase 2, Phase 3Propionic Acidemia2026-09-18recruiting
Fukuoka33.60, 130.42Japan698.82K13Phase 2, Phase 3COVID-192026-10-16recruiting